Compare IH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | BYSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 58.4M |
| IPO Year | 2020 | 2016 |
| Metric | IH | BYSI |
|---|---|---|
| Price | $1.40 | $1.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 18.8K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.18 |
| 52 Week High | $3.60 | $2.50 |
| Indicator | IH | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 48.68 |
| Support Level | N/A | $1.56 |
| Resistance Level | $1.84 | $1.83 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.17 | 22.73 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.